Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials^*

References

• Rodríguez-Otero P, Paiva B, Engelhardt M, et al. Is immunotherapy here to stay in multiple myeloma? Haematologica. 2017;102:423–432.
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Selder R, Pandurevic M, et al. Multidisziplinäre tumorboards: fakten und zufriedenheitsanalyse eines unverzichtbaren instruments von tumorzentren. DMW – Dtsch Med Wochenschr. 2017;142:e51–e60.
   PubMedGoogle Scholar
• Turesson I, Velez R, Kristinsson SY, et al. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. JCO. 2010;28:830–834.
   PubMed Web of Science ®Google Scholar
• Usmani S, Ahmadi T, Ng Y, et al. Analysis of real-world data on overall survival in multiple myeloma patients with ≥3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMID), or double refractory to a PI and an IMiD. Oncologist. 2016;21:1355–1361.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–1128.
   PubMed Web of Science ®Google Scholar
• Raab MS, Cavo M, Delforge M, et al. Multiple myeloma: practice patterns across Europe. Br J Haematol. 2016;175:66–76.
   PubMed Web of Science ®Google Scholar
• Merz M, Kellermann L, Poenisch W, et al. Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey. Ann Hematol. 2017;96:987–993.
   PubMed Web of Science ®Google Scholar
• Song X, Cong Z, Wilson K. Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States. Curr Med Res Opin. 2016;32:95–103.
   PubMed Web of Science ®Google Scholar
• Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016;175:252–264.
   PubMed Web of Science ®Google Scholar
• Rifkin RM, Abonour R, Durie BGM, et al. Treatment Patterns from 2009 to 2015 in patients with newly diagnosed multiple myeloma in the United States: a report from the Connect® MM Registry. Blood. 2016;128:4489–4489.
   Google Scholar
• Fiala M, Dukeman J, Stockerl-Goldstein K, et al. The real-world characteristics and outcomes of newly diagnosed myeloma patients ineligible for clinical trials. Clin Lymphoma Myeloma Leuk. 2017;17:e55–e56.
   PubMedGoogle Scholar
• Warren JL, Harlan LC, Stevens J, et al. Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States. JCO. 2013;31:1984–1989.
   PubMed Web of Science ®Google Scholar
• Blommestein HM, Verelst SGR, de Groot S, et al. A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model. Eur J Haematol. 2016;96:198–208.
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Dold SM, Ihorst G, et al. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica. 2016;101:1110–1119.
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Domm A-S, Dold SM, et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017;102:910–921.
   PubMed Web of Science ®Google Scholar
• Markert A, Thierry V, Kleber M, et al. Chemotherapy safety and severe adverse events in cancer patients: strategies to efficiently avoid chemotherapy errors in in- and outpatient treatment. Int J Cancer. 2009;124:722–728.
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Ihorst G, Landgren O, et al. Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years. Haematologica. 2015;100:1340–1349.
   PubMed Web of Science ®Google Scholar
• Hieke S, Kleber M, König C, et al. Conditional survival: a useful concept to provide information on how prognosis evolves over time. Clin Cancer Res. 2015;21:1530–1536.
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Berger DP, Duyster J, Mertelsmann R. Das Blaue Buch. Heidelberg: Springer; 2017.
   Google Scholar
• Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2017;28:iv52–iv61.
   PubMed Web of Science ®Google Scholar
• Gramatzki M, Günther A, Offidani M, et al. The European myeloma network EMN09 study: carfilzomib, benadmustine, and dexamethasone (CBD) is efficient and safe in patients with advanced multiple myeloma. Haematologica. 2017;102(Suppl 2):113.
   Web of Science ®Google Scholar
• Miguel JFS, Mateos M-V. Current challenges in the management of patients with relapsed/refractory multiple myeloma. Oncol Williston Park N. 2011;25(Suppl 2):10–18.
   PubMedGoogle Scholar
• Engelhardt M, Berger DP, Mertelsmann R, Duyster J. Das Blaue Buch, Chemotherapie-Manual Hämatologie und Onkologie. 6. Auflage. Berlin, Heidelberg: Springer; 2016.
   Google Scholar
• Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1782–1791.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, San Miguel JF, et al. International myeloma working group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. JCO. 2014;32:587–600.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dimopoulos MA, Kastritis E, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31:2443–2448.
   PubMed Web of Science ®Google Scholar